ProShare Advisors
CTKB icon

ProShare Advisors’s Cytek Biosciences CTKB Stock Holding History

ProShare Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.5K Sell
15,925
-2,291
-13% -$9.78K ﹤0.01% 1813
2026
Q1 		$79.6K Sell
18,216
-4,517
-20% -$21.3K ﹤0.01% 1737
2025
Q4 		$115K Buy
22,733
+729
+3% +$3.38K ﹤0.01% 1847
2025
Q3 		$76.4K Sell
22,004
-3,966
-15% -$14.9K ﹤0.01% 1878
2025
Q2 		$88.3K Sell
25,970
-1,797
-6% -$5.99K ﹤0.01% 1898
2025
Q1 		$111K Sell
27,767
-8,474
-23% -$43.9K ﹤0.01% 1814
2024
Q4 		$235K Buy
36,241
+11,213
+45% +$66.8K ﹤0.01% 1803
2024
Q3 		$139K Buy
25,028
+6,881
+38% +$39K ﹤0.01% 1822
2024
Q2 		$101K Sell
18,147
-5,794
-24% -$34.8K ﹤0.01% 1663
2024
Q1 		$161K Buy
23,941
+1,687
+8% +$13.3K ﹤0.01% 1726
2023
Q4 		$203K Buy
22,254
+4,292
+24% +$27K ﹤0.01% 1633
2023
Q3 		$99.2K Buy
17,962
+109
+0.6% +$874 ﹤0.01% 1633
2023
Q2 		$152K Buy
17,853
+4,414
+33% +$39.6K ﹤0.01% 1605
2023
Q1 		$124K Sell
13,439
-1,254
-9% -$13.5K ﹤0.01% 1555
2022
Q4 		$150K Buy
14,693
+2,106
+17% +$28.3K ﹤0.01% 1561
2022
Q3 		$185K Sell
12,587
-240
-2% -$3.12K ﹤0.01% 1426
2022
Q2 		$138K Sell
12,827
-5,479
-30% -$54.5K ﹤0.01% 1551
2022
Q1 		$197K Buy
+18,306
New +$247K ﹤0.01% 1894

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ProShare Advisors's CTKB Position: Q2 2026 in Review

ProShare Advisors reduced its Cytek Biosciences (CTKB) stake by 13% in Q2 2026, selling an estimated $9.78K and leaving 15,925 shares worth $70.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1813.

ProShare Advisors first reported a position in CTKB in Q1 2022 and has held it in 18 quarters since. The position peaked at $235K in Q4 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • ProShare Advisors held 15,925 shares of Cytek Biosciences worth $70.5K as of Q2 2026.
  • ProShare Advisors sold 2,291 Cytek Biosciences shares in Q2 2026, an estimated $9.78K.
  • Cytek Biosciences made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1813 holding.
  • ProShare Advisors first reported a position in Cytek Biosciences in Q1 2022 and has held it in 18 quarters since.
  • ProShare Advisors's Cytek Biosciences position peaked at $235K in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.